GB-0895
Severe Asthma
Key Facts
About Generate Biomedicines
Generate Biomedicines is a Flagship Pioneering company on a mission to program biology, using its proprietary Generate Platform to create novel protein therapeutics with unprecedented speed and precision. The company achieved a significant validation milestone with its IPO in March 2026, raising capital to advance a diversified pipeline led by GB-0895, a long-acting anti-TSLP antibody now in global Phase 3 studies for severe asthma. Its strategy leverages a continuous learning loop that integrates computational design with high-throughput experimental validation, aiming to build a broad portfolio of internally developed and partnered programs across immunology, oncology, and beyond.
View full company profileAbout Generate Biomedicines
Generate Biomedicines is a Flagship Pioneering company on a mission to program biology, using its proprietary Generate Platform to create novel protein therapeutics with unprecedented speed and precision. The company achieved a significant validation milestone with its IPO in March 2026, raising capital to advance a diversified pipeline led by GB-0895, a long-acting anti-TSLP antibody now in global Phase 3 studies for severe asthma. Its strategy leverages a continuous learning loop that integrates computational design with high-throughput experimental validation, aiming to build a broad portfolio of internally developed and partnered programs across immunology, oncology, and beyond.
View full company profileTherapeutic Areas
Other Severe Asthma Drugs
| Drug | Company | Phase |
|---|---|---|
| Depemokimab (GSK3511294) | GSK | Phase III |
| Spiro Neuromodulation System | Spiro Medical | Phase 2 |
| Severe Asthma (FFA4 receptor) | Keltic Pharma Therapeutics | Pre-clinical |
| KN-002 | Kinaset Therapeutics | Pre-clinical |
| FB704A | Oneness Biotech | Phase 1 |
| Verekitug (UPB-101) | Upstream Bio | Phase 2 |